methyl (S)-1-benzyloxycarbonylhexahydropyridazine-3-carboxylate | 173656-97-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (S)-1-benzyloxycarbonylhexahydropyridazine-3-carboxylate
• 英文别名: (3S)-N¹-Cbz-piperazic acid methyl ester；1-(phenylmethyl)-3-methyl (3S)-tetra-hydro-1,3(2H)-pyridazinedicarboxylate；1-O-benzyl 3-O-methyl (3S)-diazinane-1,3-dicarboxylate
• CAS: 173656-97-8
• 化学式: C₁₄H₁₈N₂O₄
• 分子量: 278.308
• InChiKey: JWGXSGXXBUOALQ-LBPRGKRZSA-N

物化性质

• 沸点：
  385.7±52.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-溴丙酰氯 、 methyl (S)-1-benzyloxycarbonylhexahydropyridazine-3-carboxylate 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以75%的产率得到1-(phenylmethyl)-3-methyl (3S)-2-(3-bromo-1-oxopropyl)tetrahydro-1,3(2H)-pyridazinedicarboxylate
  参考文献：
  名称：

  Pyridazine derivative, pharmaceutical composition thereof, its pharmaceutical use, and process for its preparation

  摘要：

  该发明涉及一种式（I）的吡啶嗪衍生物，其中变量如本文所定义，其药物组成部分，制备方法以及其药用。

  公开号：

  US20050165017A1
• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 甲醇 、 正己烷 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 methyl (S)-1-benzyloxycarbonylhexahydropyridazine-3-carboxylate
  参考文献：
  名称：

  Lipase TL-Mediated Kinetic Resolution of 5-Benzyloxy-1-tert-butyldimethylsilyloxy-2-pentanol at Low Temperature:  Concise Asymmetric Synthesis of Both Enantiomers of a Piperazic Acid Derivative

  摘要：

  Lipase TL-mediated kinetic resolution of (+/-)-5-benzyloxy-1-tert-butyldimethylsilyloxy-2-pentanol (5) at low temperature proceeded to give the corresponding (S)-alcohol 5 and (R)-acetate 6 in quantitative yields with high enantiomeric purity. The addition of bases such as pyridine, DMAP, 2,4- and 2,6-lutidines, or triethylamine considerably enhanced the rate of kinetic resolution. The alcohol (S)-5 and the acetate (R)-6 were converted to piperazic acid derivatives (R)- and (S)-3, respectively, via the intramolecular Mitsunobu reaction as a key step.

  DOI：

  10.1021/jo034441n

文献信息

• Inhibitors of interleukin-1beta converting enzyme
  申请人：Batchelor James Mark

  公开号：US20050143436A1

  公开（公告）日：2005-06-30

  The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds.

  本发明涉及一类新型化合物，这些化合物是白细胞介素-1β转化酶的抑制剂。本发明的ICE抑制剂具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制ICE活性，因此可以有利地用作对抗IL-1、凋亡、IGIF和IFN-γ介导的疾病、炎症性疾病、自身免疫疾病、破坏性骨疾病、增生性疾病、传染性疾病、退行性疾病和坏死性疾病的药剂。本发明还涉及抑制ICE活性的方法，用于治疗白细胞介素-1、凋亡、IGIF和IFN-γ介导的疾病，以及使用本发明的化合物和组合物减少IGIF和IFN-γ的产生的方法。本发明还涉及制备N-酰氨基化合物的方法。
• Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation
  申请人：Bhatnagar Neerja

  公开号：US20050215553A1

  公开（公告）日：2005-09-29

  The present invention discloses and claims hexahydropyridazine-3-carboxylic acid hydrazides and hydrazones of formula (I) as inhibitors of proteases and kinases, and methods of using said compounds of formula (I) for the prevention or treatment of certain cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers. Combinatorial libraries of the compounds of formula (I), pharmaceutical compositions, and methods for the preparation of combinatorial libraries and the compounds of formula (I) are also disclosed and claimed.

  本发明公开并声明公式（I）的六氢吡啶-3-羧酸肼和肼酮作为蛋白酶和激酶的抑制剂，并使用公式（I）的这些化合物预防或治疗某些心血管、中枢神经系统、炎症和骨病以及传染病和某些癌症。还公开并声明了公式（I）的化合物的组合式库、药物组合物以及制备组合式库和公式（I）的化合物的方法。
• Derivatives of octahydro-6,10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds
  申请人：Aventis Pharma S.A.

  公开号：US20020128473A1

  公开（公告）日：2002-09-12

  Novel intermediates of the formulae 1 where the substituents are defined as in the specification.

  新颖的中间体，其化学式中的取代基如规范中所定义。
• Total synthesis of padanamides A and B
  作者：Bohua Long、Shoubin Tang、Ligong Chen、Shiwei Qu、Bo Chen、Junyang Liu、Anita R. Maguire、Zhuo Wang、Yuqing Liu、Hui Zhang、Zhengshuang Xu、Tao Ye

  DOI：10.1039/c3cc00178d

  日期：——

  The first total syntheses of padanamides A and B have been achieved, unambiguously confirming their structures.

  首次完成了padanamides A和B的全合成，明确确认了它们的结构。
• Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation
  申请人：Bhatnagar Neerja

  公开号：US20050171346A1

  公开（公告）日：2005-08-04

  The present invention discloses and claims compounds of formula (I) as inhibitors of proteases and kinases, method using said compounds of formula (I) for the prevention or treatment of certain cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers. Combinatorial libraries of compounds of formula (I), pharmaceutical compositions and methods for preparation of combinatorial libraries and compounds of formula (I) are also disclosed and claimed.

  本发明揭示和声明了化合物的公式(I)作为蛋白酶和激酶的抑制剂，以及使用该化合物的方法，用于预防或治疗某些心血管、中枢神经系统、炎症、骨骼疾病以及传染病和某些癌症。还揭示和声明了化合物的公式(I)的组合库、制药组合物以及制备组合库和化合物的方法。